CSI Market
Sign In | Register

Elite Pharmaceuticals Inc (ELTP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ELTP Annual Cash Flow →
A period-by-period view of cash flow from Elite Pharmaceuticals Inc to Jun 30 2025 helps clarify how Jun 30 2026's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
3 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income11.73
Depreciation & amortization0.62
Amortization of Other Assets0.08
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed-0.16
Increase (Decrease) in Inventories2.94
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.03
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Warrant Derivatives-
Change In Fair Value Of Preferred Share Derivatives-
Discount In Series E Issuance Attributable To Beneficial Conversion Features-
Increase Decrease In Prepaid And Other Current Assets-
Increase Decrease In Deferred Revenue And Customer Deposits-
Accrued Compensation Non Cash-
Stock Option Plan Expense-
Noncash Rent Expense And Lease Accretion-
Increase Decrease In Contract With Customer Liability-
Derivative Gain Loss On Derivative Net2.77
Increase Decrease In Deferred Income Tax Assets-
Increase Decrease In Operating Lease Liability-0.35
Finance Lease Right Of Use Asset Amortization0.36
Income taxes0.00
Gain on Sale of Investments0.09
Increase (Decrease) in Accounts Receivable-9.44
Increase (Decrease) in Accounts Payable-0.46
Increase (Decrease) in Accrued Liabilities-3.76
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.43
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities8.83
Discontinued operations0.00
Net Cash flow from Operating Activities10.07
Investing Activities
Capital Expenditures-0.81
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.81
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.02
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.10
Proceeds From Issuance Of Series E Convertible Preferred Stock-
Proceed From Issuance Of Series E Convertible Preferred Stock And Warrants-
Proceeds from Draws Against Treppel Credit Line-
Proceeds From Draws Against Treppel Credit Line-
Other Loan Payments-
Other Loan Payment-
Proceeds From Amortization Of Finance Leases Rightofuse Assets-
Stock Issued In Satisfaction Of Accrued Directors Salaries And Consultant Fees-
Recognition Of Right Of Use Asset And Lease Liabilities-
Finance Lease Principal Payments-0.28
Finance Directors And Officers Insurance Premium-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.11
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow9.26
Total Cash Flow9.15
4 historic quarters locked

Sign in to unlock the full Elite Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Elite Pharmaceuticals Inc Nv Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037752

Figures are derived from filed reports and may be restated. Historical data is subject to revision.